In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will acquire treatment right up until sickness progression or maybe the contributors are not able to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells per replicate had https://abbv-744-brd4-inhibitor-c13467.blogdemls.com/31835349/top-brd4-inhibition-by-abbv-744-in-cancer-research-studies-secrets